The Blackstone Group led the $2.3bn investment in Precision Medicine Group, a specialized services company supporting next generation approaches to drug development and commercialization. Other investors include JH Whitney Capital Partners, Vida Ventures, TPG Capital and Berkshire Partners. "We have high conviction in the unprecedented wave of innovation PMG’s clients are driving in personalized medicines and novel drug mechanisms, especially in oncology and rare disease. PMG integrates deep science, extensive biomarker and genetic data, evidence of economic value, and market access insights to improve the speed, cost, and success rates of bringing life-changing therapies to patients. We are excited to support the continued expansion of PMG’s platform and broad therapeutic reach," Anushka Sunder, Blackstone Managing Director.